Browsing Centre for Endocrinology by Title
Now showing items 125-144 of 552
-
Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism
(The Endocrine Society, 2023-05-08) -
Effects of the COVID-19 pandemic on the incidence of central precocious puberty; a narrative review.
(2024-02-26)Central precocious puberty (CPP) is the premature activation of the hypothalamus-pituitary-gonadal axis, resulting in the early development of secondary sexual characteristics. CPP classically occurs before the age of 8 ... -
Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.
(2018)Introduction: Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations are responsible for 15-30% of familial isolated pituitary adenomas (FIPAs). We report a FIPA kindred with a heterozygous deletion in AIP, ... -
ENDO-ERN expert opinion on the differential diagnosis of pubertal delay.
(2021-01-29)The differential diagnoses of pubertal delay include hypergonadotropic hypogonadism and congenital hypogonadotropic hypogonadism (CHH), as well as constitutional delay of growth and puberty (CDGP). Distinguishing between ... -
Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors.
(2021-10-03)Somatostatin receptor subtype 5 (SST5 ) is an emerging biomarker and actionable target in pituitary (PitNETs) and pancreatic (PanNETs) neuroendocrine tumors. Transcriptional and epigenetic regulation of SSTR5 gene expression ... -
ESE audit on management of adult growth hormone deficiency in clinical practice
(2020-12)Guidelines recommend adults with pituitary disease in whom GH therapy is contemplated, to be tested for GH deficiency (AGHD); however, clinical practice is not uniform. Aims: 1) To record current practice of AGHD management ...